about
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesisAn inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cellsModulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cellsSafety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects.Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.Recent advances in antimultiple myeloma drug development.Bcl-B expression in human epithelial and nonepithelial malignancies.Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway.Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3.Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 proteinVDAC1: from structure to cancer therapy.Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Therapeutic Potential of Resveratrol in Lymphoid Malignancies.Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77.Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myelomaDysfunction of microRNA-32 regulates ubiquitin ligase FBXW7 in multiple myeloma diseaseFlavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.
P2860
Q24654905-BEF86E17-03B6-457C-BED8-C5626880099DQ28486021-222CCDC0-7921-4CCE-A98A-6B1C672D590BQ28544009-8CC48D96-98D0-4B95-9A04-E52396CC0DDCQ31042239-833E4F0D-4A5D-45C3-BAA7-81E77E0FCA28Q31160552-CE05F2A4-A944-42EE-9AF0-00E34E1F7B61Q33416297-5658D738-5C9B-4DE6-BF26-5270039B6A5FQ34224114-E93D7A74-252E-4021-BCC3-4F493AF9FB2AQ34432852-0F1CFC24-CCF1-48A9-BD04-2EC4A744026FQ35172476-E4C037E3-DF17-4E5F-92DA-1BF0615CF5EFQ35833040-A0E3D019-8E81-4F0D-A424-86D766B1DF23Q35962054-58856F1E-EF0D-4556-9D4C-477CCF34F8EAQ36080596-D32BF993-17C2-44E5-826F-8D8DCFB2ECCFQ36450079-2770528F-6D45-4B8B-8941-E2DF667F0F50Q36544094-18AF4E20-ACB8-4F13-8991-A5E2A6268160Q36916348-0357F26C-0689-47E7-9ED8-D5247E4E2115Q38637652-9AFA5CC6-D954-405A-A160-70EB05A05098Q38793825-8186F162-C7D6-4A60-BEBD-6347824E2833Q38930818-4EC8499D-1F4E-42B8-93B9-884E6D565E33Q39638460-3BA543CF-AF12-4C3A-9A6D-4FC0878F6CE4Q41628471-8D015B7C-9681-45BE-99DB-91C873CC049DQ46640442-CD23DA5D-148A-48A7-BC31-DA28477A55DEQ47633998-429491BF-6013-4F20-8658-56C6D9F3CD74Q53682262-505EDCDD-1D59-4896-89BB-97BF99008109
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Apoptosis of multiple myeloma.
@ast
Apoptosis of multiple myeloma.
@en
type
label
Apoptosis of multiple myeloma.
@ast
Apoptosis of multiple myeloma.
@en
prefLabel
Apoptosis of multiple myeloma.
@ast
Apoptosis of multiple myeloma.
@en
P2093
P2860
P356
P1476
Apoptosis of multiple myeloma
@en
P2093
Aruna Mani
Marcela Oancea
Mohamad A Hussein
P2860
P2888
P304
P356
10.1532/IJH97.04107
P50
P577
2004-10-01T00:00:00Z
P6179
1027511797